HVCM
ENSC icon

HG Vora Capital Management’s Ensysce Biosciences ENSC Stock Holding History

HG Vora Capital Management’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-684
Closed -$529K – 20
2022
Q3 		$529K Hold
684
– – 0.02% 17
2022
Q2 		$2.14M Hold
684
– – 0.08% 20
2022
Q1 		$2.81M Hold
684
– – 0.08% 28
2021
Q4 		$11.6M Hold
684
– – 0.41% 23
2021
Q3 		$7.46M Buy
+684
New +$13.4M 0.28% 24

Other funds holding ENSC

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

HG Vora Capital Management's ENSC Position: Q4 2022 in Review

HG Vora Capital Management sold out of Ensysce Biosciences (ENSC) in Q4 2022, closing a stake of 684 shares — an estimated $529K sold.

HG Vora Capital Management first reported a position in ENSC in Q3 2021 and held it in 5 quarters. The position peaked at $11.6M in Q4 2021. 13 funds tracked by Wall St. Rank hold ENSC as of Q4 2022.

  • HG Vora Capital Management reported no remaining Ensysce Biosciences position as of Q4 2022 after selling out during the quarter.
  • HG Vora Capital Management sold 684 Ensysce Biosciences shares in Q4 2022, an estimated $529K.
  • HG Vora Capital Management first reported a position in Ensysce Biosciences in Q3 2021 and held it in 5 quarters.
  • HG Vora Capital Management's Ensysce Biosciences position peaked at $11.6M in Q4 2021.
  • 13 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q4 2022.

Based on HG Vora Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.